u/Necessary_Thanks7216 · 633d agono track record yet
Are you an expert in your field of work? If so, which stocks in that sector are you bullish on?
Novo Nordisk's Semaglutide is a category-defining GLP-1 agonist with massive addressable markets in diabetes and obesity. Despite competitive threats from Lilly and others, NVO has superior valuation metrics (lower P/S at 10x vs Lilly's 18x, better margins and cash flow), better long-term R&D positioning, and demonstrated cardiovascular benefits. The author, an endocrinologist, projects sustained revenue and profit growth over 5+ years with outperformance versus the S&P 500.
At post $77.89Now $39.05-49.9% since postedas of Oct 23, 4:45 PM ET
1d+1.6%
3d+0.5%
1w+2.0%
1m+7.9%
3m-21.2%
6m-16.6%
1y-27.4%